- Home
- PRQR vs OCCI Comparison
PRQR vs OCCI Comparison
Compare PRQR & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- OCCI
- Stock Information
- Founded
- PRQR 2012
- OCCI N/A
- Country
- PRQR Netherlands
- OCCI United States
- Employees
- PRQR N/A
- OCCI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- PRQR Health Care
- OCCI Finance
- Exchange
- PRQR Nasdaq
- OCCI Nasdaq
- Market Cap
- PRQR 179.1M
- OCCI 160.5M
- IPO Year
- PRQR 2014
- OCCI N/A
- Fundamental
- Price
- PRQR $2.30
- OCCI $6.25
- Analyst Decision
- PRQR Strong Buy
- OCCI
- Analyst Count
- PRQR 8
- OCCI 0
- Target Price
- PRQR $8.88
- OCCI N/A
- AVG Volume (30 Days)
- PRQR 362.3K
- OCCI 115.8K
- Earning Date
- PRQR 08-07-2025
- OCCI 12-11-2023
- Dividend Yield
- PRQR N/A
- OCCI 24.32%
- EPS Growth
- PRQR N/A
- OCCI N/A
- EPS
- PRQR N/A
- OCCI N/A
- Revenue
- PRQR $21,212,711.00
- OCCI N/A
- Revenue This Year
- PRQR N/A
- OCCI N/A
- Revenue Next Year
- PRQR N/A
- OCCI $10.19
- P/E Ratio
- PRQR N/A
- OCCI N/A
- Revenue Growth
- PRQR 85.91
- OCCI N/A
- 52 Week Low
- PRQR $1.07
- OCCI $5.47
- 52 Week High
- PRQR $4.62
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- PRQR 68.07
- OCCI 51.80
- Support Level
- PRQR $2.10
- OCCI $5.88
- Resistance Level
- PRQR $2.18
- OCCI $6.30
- Average True Range (ATR)
- PRQR 0.13
- OCCI 0.09
- MACD
- PRQR 0.01
- OCCI 0.02
- Stochastic Oscillator
- PRQR 54.55
- OCCI 77.08
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation primarily through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.